 
Glenmark Pharmaceuticals Limited 
Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India 
T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com 
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026  E: complianceofficer@glenmarkpharma.com 
 
November 14, 2025  
To,       To, 
Dy. General Manager The Manager – Listing,   
Department of Corporate Services,               The National Stock Exchange of India Ltd., 
BSE Ltd.,                                           Plot No. C/1, G Block, 
P. J. Towers, Dalal Street,    Bandra Kurla Complex, 
Fort, Mumbai – 400 001                                         Bandra (E), Mumbai – 400 051 
 
Ref: Scrip Code: 532296                Ref: Scrip Name: GLENMARK 
 
Dear Sir, 
Sub: Intimation of Schedule of Analyst / Institutional Investor Meetings 
Pursuant to the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) 
Regulations, 2015, we would like to inform the details of Analyst / Institutional Investor meetings 
to be conducted as follows: 
Date Analyst/Institutional 
Investors/Event Venue Type of 
Meeting 
Group / 
One-on-
one 
19 November 
2025 
Avendus Spark Annual 
Investor Conference 2025 
Mumbai Physical Both 
 
The company will not be disclosing any Unpublished Price Sensitive Information (UPSI) at these 
meetings. The schedule of the above-mentioned meetings is subject to change due to exigencies 
on the part of Investor / Company. 
We request you to take this intimation on record.  
Thanking you, 
 
Yours faithfully, 
For Glenmark Pharmaceuticals Limited 
 
 
 
Harish Kuber  
Company Secretary & Compliance Officer 
